Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) major shareholder Redmile Group, Llc bought 400,000 shares of Attovia Therapeutics stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, with a total value of $6,800,000.00. Following the acquisition, the insider owned 1,182,854 shares of the company’s stock, valued at $20,108,518. The trade was a 51.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Attovia Therapeutics Stock Performance
NASDAQ ATTO traded down $0.21 on Friday, reaching $20.17. 237,906 shares of the company’s stock traded hands, compared to its average volume of 325,553. Attovia Therapeutics, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $22.79.
Institutional Trading of Attovia Therapeutics
An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. lifted its position in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.
Attovia Therapeutics Company Profile
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Further Reading
- Five stocks we like better than Attovia Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
